Under the agreement, the companies will advance development of IBI3009, Innovent’s ADC candidate, which has received IND approvals in the US, China, and Australia.
The European Commission has approved Novo Holdings' acquisition of Catalent, which includes the related sale of three manufacturing sites to Novo Nordisk, which is also acquiring the Czech Republic ...
It is important to understand the differences between risk-based decision making and other decision making in a pharmaceutical quality system.
CHMP has granted Eisai Europe and Biogen a positive opinion for the use of their monoclonal antibody therapy in treating early Alzheimer’s disease.
Optimizing Drug Packaging: Strategic Approaches for De-Risking Drug Development ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果